Paying user area
Try for free
Zoetis Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Zoetis Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenue1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 13, 2024 | = | ÷ | = | ÷ | |||||||
Feb 14, 2023 | = | ÷ | = | ÷ | |||||||
Feb 15, 2022 | = | ÷ | = | ÷ | |||||||
Feb 16, 2021 | = | ÷ | = | ÷ | |||||||
Feb 13, 2020 | = | ÷ | = | ÷ | |||||||
Feb 14, 2019 | = | ÷ | = | ÷ | |||||||
Feb 15, 2018 | = | ÷ | = | ÷ | |||||||
Feb 16, 2017 | = | ÷ | = | ÷ | |||||||
Feb 24, 2016 | = | ÷ | = | ÷ | |||||||
Feb 27, 2015 | = | ÷ | = | ÷ | |||||||
Mar 26, 2014 | = | ÷ | = | ÷ | |||||||
Mar 28, 2013 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Zoetis Inc. Annual Report.
The analysis of the recent annual financial data reveals several notable trends in the company's market valuation and operational performance over the examined period.
- Share Price
- The share price demonstrates an overall upward trajectory from US$33.40 in March 2013 to US$183.49 in February 2024. This represents a more than fivefold increase over the 11-year span. Despite some fluctuations, notably a decline from US$197.76 in February 2022 to US$171.90 in February 2023, the price rebounded to US$183.49 by February 2024. The most significant gains occurred between 2019 and 2022, indicating periods of heightened market confidence.
- Sales Per Share
- Sales per share steadily increased from US$8.67 in March 2013 to US$18.66 in February 2024. The growth is consistent and gradual, reflecting an improvement in the company's revenue generation capacity on a per-share basis. Notably, the rise was uninterrupted even during periods when share price experienced volatility, suggesting operational strength independent of market valuation swings.
- Price-to-Sales Ratio (P/S)
- The price-to-sales ratio exhibits variability over time but generally trends upward, moving from 3.85 in 2013 to a peak of 12.00 in February 2022 before declining slightly to 9.83 in February 2024. This indicates that the market has increasingly valued each dollar of sales at a higher multiple across most of the period, reflecting enhanced investor expectations or improved profitability prospects. The decrease in the P/S ratio in the last two years suggests a recalibration of market valuation relative to sales, possibly due to normalization after a period of strong speculative interest or valuation adjustment.
In summary, the data shows a solid long-term increase in sales per share alongside a substantial growth in share price, signaling robust business performance and positive market sentiment. The fluctuations in the price-to-sales ratio highlight changing investor perceptions regarding valuation, with a notable peak prior to a modest correction. Overall, these patterns reflect a company that has consistently expanded its sales base and enjoyed market appreciation, albeit with periodic valuation adjustments.
Comparison to Competitors
Zoetis Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb 13, 2024 | |||||||||||||
Feb 14, 2023 | |||||||||||||
Feb 15, 2022 | |||||||||||||
Feb 16, 2021 | |||||||||||||
Feb 13, 2020 | |||||||||||||
Feb 14, 2019 | |||||||||||||
Feb 15, 2018 | |||||||||||||
Feb 16, 2017 | |||||||||||||
Feb 24, 2016 | |||||||||||||
Feb 27, 2015 | |||||||||||||
Mar 26, 2014 | |||||||||||||
Mar 28, 2013 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Zoetis Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Zoetis Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Feb 13, 2024 | ||
Feb 14, 2023 | ||
Feb 15, 2022 | ||
Feb 16, 2021 | ||
Feb 13, 2020 | ||
Feb 14, 2019 | ||
Feb 15, 2018 | ||
Feb 16, 2017 | ||
Feb 24, 2016 | ||
Feb 27, 2015 | ||
Mar 26, 2014 | ||
Mar 28, 2013 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
Zoetis Inc. | Health Care | |
---|---|---|
Feb 13, 2024 | ||
Feb 14, 2023 | ||
Feb 15, 2022 | ||
Feb 16, 2021 | ||
Feb 13, 2020 | ||
Feb 14, 2019 | ||
Feb 15, 2018 | ||
Feb 16, 2017 | ||
Feb 24, 2016 | ||
Feb 27, 2015 | ||
Mar 26, 2014 | ||
Mar 28, 2013 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).